OraSure Technologies Inc (OSUR): רווח נקי למניה (EPS TTM)

Steady demand from government clinics for OraSure Technologies (OSUR) tests supports revenues, which, combined with external raw material supplies and full control over assembly, determines the 12-month net income per share dynamics. The -0.70 mark characterizes this parameter, confirming financial stability. Future growth is expected to be driven by business diversification and the development of molecular diagnostics.

For OraSure Technologies (OSUR), a leader in the rapid saliva diagnostics segment, this indicator combines the efficiency of FDA-approved solutions with the business's final profitability per share. By analyzing the rolling trailing twelve-month earnings per share, an investor assesses the net remaining funds after all expenses and taxes, confirming the company's ability to convert its technological advantage into sustainable capital growth.